{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:28:33Z","timestamp":1793212113873,"version":"4.5.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T00:00:00Z","timestamp":1618963200000},"content-version":"am","delay-in-days":355,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.cgh.2020.02.009","type":"journal-article","created":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T06:11:36Z","timestamp":1581487896000},"page":"1324-1335.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":133,"title":["Predicting, Preventing, and Managing Treatment-Related Complications in Patients With Inflammatory Bowel Diseases"],"prefix":"10.1016","volume":"18","author":[{"given":"Laurent","family":"Beaugerie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Rahier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Kirchgesner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2020.02.009_bib1","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.cgh.2018.07.013","article-title":"Balancing benefit vs risk of immunosuppressive therapy for individual patients with inflammatory bowel diseases","volume":"17","author":"Beaugerie","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2020.02.009_bib2","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa043335","article-title":"Natalizumab induction and maintenance therapy for Crohn\u2019s disease","volume":"353","author":"Sandborn","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2020.02.009_bib3","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2020.02.009_bib4","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S0140-6736(89)92407-0","article-title":"Cardiac hypersensitivity to 5-aminosalicylic acid","volume":"1","author":"Agnholt","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2020.02.009_bib5","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1053\/j.gastro.2012.05.004","article-title":"Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease","volume":"143","author":"Long","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2020.02.009_bib6","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/apt.13466","article-title":"Excess risk of urinary tract cancers in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study","volume":"43","author":"Bourrier","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2020.02.009_bib7","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1111\/apt.14688","article-title":"Systematic review: safety of mesalazine in ulcerative colitis","volume":"47","author":"Sehgal","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2020.02.009_bib8","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/apt.15097","article-title":"Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease","volume":"49","author":"Shivaji","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2020.02.009_bib9","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/14740338.2019.1612874","article-title":"Safety of drugs used for the treatment of Crohn\u2019s disease","volume":"18","author":"Pudipeddi","year":"2019","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.cgh.2020.02.009_bib10","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1080\/14740338.2017.1340936","article-title":"The safety of non-biological treatments in ulcerative colitis","volume":"16","author":"Troncone","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.cgh.2020.02.009_bib11","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/jama.2019.0709","article-title":"Association of genetic variants in NUDT15 with thiopurine-induced myelosuppression in patients with inflammatory bowel disease","volume":"321","author":"Walker","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.cgh.2020.02.009_bib12","doi-asserted-by":"crossref","first-page":"891","DOI":"10.2217\/pgs.15.29","article-title":"Update on thiopurine pharmacogenetics in inflammatory bowel disease","volume":"16","author":"Roberts","year":"2015","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.cgh.2020.02.009_bib13","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1053\/j.gastro.2018.04.012","article-title":"Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases","volume":"155","author":"Kirchgesner","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2020.02.009_bib14","doi-asserted-by":"crossref","first-page":"h2809","DOI":"10.1136\/bmj.h2809","article-title":"Association between tumour necrosis factor-\u03b1 inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study","volume":"350","author":"Nyboe Andersen","year":"2015","journal-title":"BMJ"},{"key":"10.1016\/j.cgh.2020.02.009_bib15","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/ajg.2012.218","article-title":"Serious infection and mortality in patients with Crohn\u2019s disease: more than 5 years of follow-up in the TREATTM registry","volume":"107","author":"Lichtenstein","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2020.02.009_bib16","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1053\/j.gastro.2017.02.004","article-title":"Infliximab is not associated with increased risk of malignancy or hemophagocytic lymphohistiocytosis in pediatric patients with inflammatory bowel disease","volume":"152","author":"Hyams","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2020.02.009_bib17","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/apt.14933","article-title":"Impact of Epstein-Barr virus serological status on clinical outcomes in adult patients with inflammatory bowel disease","volume":"48","author":"Francisco","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2020.02.009_bib18","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn\u2019s disease","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2020.02.009_bib19","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1001\/jamadermatol.2019.1121","article-title":"Risk of serious infection in patients receiving systemic medications for the treatment of psoriasis","volume":"155","author":"Dommasch","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.cgh.2020.02.009_bib20","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1093\/ibd\/izy131","article-title":"Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib","volume":"24","author":"Winthrop","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2020.02.009_bib21","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1038\/ajg.2015.284","article-title":"Inflammatory bowel disease patients are at increased risk of invasive pneumococcal disease: a nationwide Danish cohort study 1977\u20132013","volume":"110","author":"Kants\u00f8","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2020.02.009_bib22","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.cgh.2006.09.019","article-title":"Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease","volume":"4","author":"Gupta","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2020.02.009_bib23","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/j.cgh.2018.12.032","article-title":"Safety of biologic therapy in older patients with immune-mediated diseases: a systematic review and meta-analysis","volume":"17","author":"Borren","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2020.02.009_bib24","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1111\/j.1572-0241.2008.02050.x","article-title":"Comparison of interferon-gamma release assay versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease","volume":"103","author":"Schoepfer","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2020.02.009_bib25","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/ibd.21427","article-title":"Factors impacting the results of interferon-\u03b3 release assay and tuberculin skin test in routine screening for latent tuberculosis in patients with inflammatory bowel diseases","volume":"17","author":"Papay","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2020.02.009_bib26","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.crohns.2013.12.013","article-title":"Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease","volume":"8","author":"Rahier","year":"2014","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2020.02.009_bib27","first-page":"18","article-title":"Severe strongyloidiasis in corticosteroid-treated patients: case series and literature review","volume":"54","author":"Fardet","year":"2007","journal-title":"J\u00a0Infect"},{"key":"10.1016\/j.cgh.2020.02.009_bib28","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/gut.2010.208413","article-title":"Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy","volume":"59","author":"Loras","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2020.02.009_bib29","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1365-2036.2010.04558.x","article-title":"Influenza A (H1N1)v infection in patients with inflammatory bowel disease: a case series","volume":"33","author":"Rahier","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2020.02.009_bib30","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/ecco-jcc\/jjv064","article-title":"Vaccination in inflammatory bowel disease patients: attitudes, knowledge, and uptake","volume":"9","author":"Malhi","year":"2015","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2020.02.009_bib31","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/17474124.2019.1565993","article-title":"Updates on vaccinating the inflammatory bowel disease patient","volume":"13","author":"Zullow","year":"2019","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2020.02.009_bib32","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/ajg.2016.537","article-title":"ACG Clinical Guideline: preventive care in inflammatory bowel disease","volume":"112","author":"Farraye","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2020.02.009_bib33","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/BOR.0b013e3282ffdeca","article-title":"Immunization of patients with rheumatoid arthritis with antitumor necrosis factor alpha therapy and methotrexate","volume":"20","author":"Brezinschek","year":"2008","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.cgh.2020.02.009_bib34","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1093\/rheumatology\/keq183","article-title":"Vaccinations in patients with immune-mediated inflammatory diseases","volume":"49","author":"Rahier","year":"2010","journal-title":"Rheumatol Oxf Engl"},{"key":"10.1016\/j.cgh.2020.02.009_bib35","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1097\/MIB.0000000000000406","article-title":"Immunogenicity of 13-valent pneumococcal conjugate vaccine in pediatric patients with inflammatory bowel disease","volume":"21","author":"Banaszkiewicz","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2020.02.009_bib36","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/MIB.0000000000000615","article-title":"Immunogenicity of influenza vaccine for patients with inflammatory bowel disease on maintenance infliximab therapy: a randomized trial","volume":"22","author":"deBruyn","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2020.02.009_bib37","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1097\/MIB.0000000000000743","article-title":"Herpes zoster vaccine response in inflammatory bowel disease patients on low-dose immunosuppression","volume":"22","author":"Wasan","year":"2016","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2020.02.009_bib38","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.cgh.2012.09.026","article-title":"Trends in overall and cause-specific mortality among patients with inflammatory bowel disease from 1982 to 2010","volume":"11","author":"Jess","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2020.02.009_bib39","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1056\/NEJMra1403718","article-title":"Cancers complicating inflammatory bowel disease","volume":"372","author":"Beaugerie","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2020.02.009_bib40","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","article-title":"Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study","volume":"374","author":"Beaugerie","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2020.02.009_bib41","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1136\/gut.2004.049460","article-title":"Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine","volume":"54","author":"Kandiel","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2020.02.009_bib42","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1001\/jama.2014.5613","article-title":"Association between tumor necrosis factor-\u03b1 antagonists and risk of cancer in patients with inflammatory bowel disease","volume":"311","author":"Nyboe Andersen","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.cgh.2020.02.009_bib43","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2017.16071","article-title":"Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease","volume":"318","author":"Lemaitre","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.cgh.2020.02.009_bib44","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jaad.2017.07.013","article-title":"Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry","volume":"77","author":"Fiorentino","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.cgh.2020.02.009_bib45","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.cgh.2014.05.015","article-title":"Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis","volume":"13","author":"Kotlyar","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2020.02.009_bib46","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1136\/gutjnl-2014-307126","article-title":"Systematic review: monotherapy with antitumour necrosis factor \u03b1 agents versus combination therapy with an immunosuppressive for IBD","volume":"63","author":"Dulai","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2020.02.009_bib47","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/ecco-jcc\/jjv141","article-title":"European evidence-based consensus: inflammatory bowel disease and malignancies","volume":"9","author":"Annese","year":"2015","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2020.02.009_bib48","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jdermsci.2016.09.003","article-title":"Non-genetic risk factors for cutaneous melanoma and keratinocyte skin cancers: an umbrella review of meta-analyses","volume":"84","author":"Belbasis","year":"2016","journal-title":"J\u00a0Dermatol Sci"},{"key":"10.1016\/j.cgh.2020.02.009_bib49","doi-asserted-by":"crossref","first-page":"782","DOI":"10.12659\/AOT.910658","article-title":"Colonoscopy as part of pre-transplant work-up in successful kidney transplant candidates: single-center experience and review of literature","volume":"23","author":"Kobiela","year":"2018","journal-title":"Ann Transplant"},{"key":"10.1016\/j.cgh.2020.02.009_bib50","doi-asserted-by":"crossref","DOI":"10.1177\/1756284818817293","article-title":"Practical guidance for the management of inflammatory bowel disease in patients with cancer. Which treatment?","volume":"12","author":"Sebastian","year":"2019","journal-title":"Ther Adv Gastroenterol"},{"key":"10.1016\/j.cgh.2020.02.009_bib51","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1093\/annonc\/mdn054","article-title":"A\u00a0clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer","volume":"19","author":"Brown","year":"2008","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.cgh.2020.02.009_bib52","first-page":"18","article-title":"A\u00a0multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia","volume":"6","author":"Wiedenmann","year":"2008","journal-title":"J\u00a0Support Oncol"},{"key":"10.1016\/j.cgh.2020.02.009_bib53","series-title":"New malignancies among cancer survivors: SEER cancer registries, 1993-2000. National Institutes of Health publication number 05-5302","author":"Curtis","year":"2006"},{"key":"10.1016\/j.cgh.2020.02.009_bib54","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1136\/gutjnl-2013-305763","article-title":"Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer","volume":"63","author":"Beaugerie","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2020.02.009_bib55","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.cgh.2015.07.037","article-title":"Risk of new or recurrent cancer in patients with inflammatory bowel disease and previous cancer exposed to immunosuppressive and anti-tumor necrosis factor agents","volume":"14","author":"Axelrad","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2020.02.009_bib56","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/j.gastro.2016.03.037","article-title":"Cancer recurrence following immune-suppressive therapies in patients with immune-mediated diseases: a systematic review and meta-analysis","volume":"151","author":"Shelton","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2020.02.009_bib57","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/acr.20129","article-title":"Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register","volume":"62","author":"Dixon","year":"2010","journal-title":"Arthritis Care Res Hoboken"},{"key":"10.1016\/j.cgh.2020.02.009_bib58","doi-asserted-by":"crossref","first-page":"R5","DOI":"10.1186\/ar2904","article-title":"Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT","volume":"12","author":"Strangfeld","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.cgh.2020.02.009_bib59","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2020.02.009_bib60","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1097\/00007890-199304000-00011","article-title":"The effect of immunosuppression on pre-existing cancers","volume":"55","author":"Penn","year":"1993","journal-title":"Transplantation"},{"key":"10.1016\/j.cgh.2020.02.009_bib61","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","article-title":"Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial","volume":"381","author":"Davies","year":"2013","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.cgh.2020.02.009_bib62","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jamcollsurg.2013.03.007","article-title":"Late recurrence in melanoma: clinical implications of lost dormancy","volume":"217","author":"Faries","year":"2013","journal-title":"J\u00a0Am Coll Surg"},{"key":"10.1016\/j.cgh.2020.02.009_bib63","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/ibd.21330","article-title":"Incidence of nodular regenerative hyperplasia in inflammatory bowel disease patients treated with azathioprine","volume":"17","author":"Seksik","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2020.02.009_bib64","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/nrrheum.2011.35","article-title":"Autoimmune-like syndromes during TNF blockade: does infection have a role?","volume":"7","author":"Prinz","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.cgh.2020.02.009_bib65","first-page":"CD006097","article-title":"Natalizumab for induction of remission in Crohn\u2019s disease","volume":"8","author":"Nelson","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cgh.2020.02.009_bib66","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cgh.2010.09.016","article-title":"A\u00a0systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease","volume":"9","author":"Kotlyar","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2020.02.009_bib67","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.cgh.2014.02.026","article-title":"Increased risk of acute myeloid leukemias and myelodysplastic syndromes in patients who received thiopurine treatment for inflammatory bowel disease","volume":"12","author":"Lopez","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2020.02.009_bib68","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1053\/j.gastro.2011.06.050","article-title":"Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease","volume":"141","author":"Peyrin-Biroulet","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2020.02.009_bib69","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1038\/ajg.2014.298","article-title":"Risk of melanoma and non-melanoma skin cancer in ulcerative colitis patients treated with thiopurines: a nationwide retrospective cohort","volume":"109","author":"Abbas","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2020.02.009_bib70","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-dose methotrexate for the prevention of atherosclerotic events","volume":"380","author":"Ridker","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2020.02.009_bib71","doi-asserted-by":"crossref","first-page":"E711","DOI":"10.1002\/ijc.29209","article-title":"Risk of cervical cancer in women with autoimmune diseases, in relation with their use of immunosuppressants and screening: population-based cohort study","volume":"136","author":"Dugu\u00e9","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cgh.2020.02.009_bib72","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1053\/j.gastro.2018.04.012","article-title":"Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases","volume":"155","author":"Kirchgesner","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2020.02.009_bib73","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/j.cgh.2018.12.032","article-title":"Safety of biologic therapy in older patients with immune-mediated diseases: a systematic review and meta-analysis","volume":"17","author":"Borren","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2020.02.009_bib74","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1093\/ibd\/izy131","article-title":"Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib","volume":"24","author":"Winthrop","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2020.02.009_bib75","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/SLA.0000000000002017","article-title":"Anti-TNF therapy is associated with an increased risk of postoperative morbidity after surgery for ileocolonic Crohn disease: results of a prospective nationwide cohort","volume":"267","author":"Brouquet","year":"2018","journal-title":"Ann Surg"},{"key":"10.1016\/j.cgh.2020.02.009_bib76","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/ajg.2016.541","article-title":"Postoperative complications after ileocecal resection in Crohn\u2019s disease: a prospective study from the REMIND group","volume":"112","author":"Fumery","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2020.02.009_bib77","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/apt.14459","article-title":"Postoperative outcomes in vedolizumab-treated Crohn\u2019s disease patients undergoing major abdominal operations","volume":"47","author":"Lightner","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2020.02.009_bib78","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/ecco-jcc\/jjy022","article-title":"Systematic review and meta-analysis: preoperative vedolizumab treatment and postoperative complications in patients with inflammatory bowel disease","volume":"12","author":"Law","year":"2018","journal-title":"J\u00a0Crohns Colitis"},{"key":"10.1016\/j.cgh.2020.02.009_bib79","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1053\/j.gastro.2008.01.012","article-title":"Risk factors for opportunistic infections in patients with inflammatory bowel disease","volume":"134","author":"Toruner","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2020.02.009_bib80","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/rheumatology\/kem076","article-title":"Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis","volume":"46","author":"Bernatsky","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.cgh.2020.02.009_bib81","doi-asserted-by":"crossref","DOI":"10.1001\/jamadermatol.2019.1121","article-title":"Risk of serious infection in patients receiving systemic medications for the treatment of psoriasis","author":"Dommasch","year":"2019","journal-title":"JAMA Dermatol"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356520301737?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356520301737?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:31:51Z","timestamp":1761543111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356520301737"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":81,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S1542356520301737"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2020.02.009","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predicting, Preventing, and Managing Treatment-Related Complications in Patients With Inflammatory Bowel Diseases","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2020.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the AGA Institute","name":"copyright","label":"Copyright"}]}}